Pharmaceutical R&D stands at a pivotal inflection point, witnessing a profound transformation in how diseases are targeted and treated. The traditional dichotomy between small molecules and large molecules, long a fundamental organizing principle in drug discovery, is rapidly dissolving, giving way to a more intricate, hybrid-driven landscape. This evolution is driven by unprecedented scientific advancements, the relentless pursuit of precision medicine, and the revolutionary impact of artificial intelligence.
The Shifting Pharmaceutical Landscape: A Paradox of Growth
Recent data highlights a compelling paradox in the pharmaceutical market. In 2025, small molecules accounted for a notable 65% of novel drug approvals by the FDA, a significant jump from 56% in both 2023 and 2024. This resurgence occurs even as biologic sales are experiencing a growth rate three times faster than their chemical counterparts, with projections indicating they will surpass small molecule sales by 2027. This seeming contradiction underscores the dynamic tension and concurrent innovation shaping the industry.
The global pharmaceutical market, valued at an estimated $828 billion in 2018, saw small molecules contributing 69% of sales and biologics 31%. By 2023, the market had expanded to $1.344 trillion, with small molecules holding 58% and biologics capturing 42%. The accelerated growth of biologics is undeniable, driven by breakthroughs in complex therapeutic areas and an expanding understanding of disease mechanisms. However, the consistent flow of small molecule approvals, particularly the recent uptick, signals a robust renaissance fueled by new technologies and strategic shifts.
The Era of Precision: Targeting with Unprecedented Specificity
The overarching trajectory of drug discovery is a decisive shift from broad-spectrum interventions to highly precise, targeted medicine. This paradigm change is underpinned by remarkable advances in genomics, sophisticated target biology, and the transformative power of artificial intelligence. Researchers are now equipped to identify and engage disease pathways with far greater specificity than ever before, moving away from a generalized approach to a highly focused attack.
"It’s no longer trying to shotgun blast a whole bunch of things, but instead trying to sniper and be really tight in what we’re attacking," explains Andreas Matern, vice president of professional services at Elsevier. This sentiment captures the industry’s evolving mindset, where deep biological intelligence precedes modality commitment. Pharmaceutical companies are increasingly investing in understanding the target, the genomic landscape, and the specific patient population before initiating development, thereby optimizing the chances of success and minimizing late-stage failures.
AI as the Catalyst: Compressing Timelines and Enhancing Decision-Making
Artificial intelligence is not merely an auxiliary tool; it is rapidly becoming an indispensable engine driving pharmaceutical R&D. AI algorithms are compressing discovery timelines, generating novel hypotheses, and providing critical insights that inform modality selection. Groundbreaking AI tools such as AlphaFold, which predicts protein structures with remarkable accuracy, generative chemistry platforms designing novel compounds, and large language models capable of extracting patterns from vast datasets, are being layered onto proprietary and public scientific data. This integration unlocks previously inaccessible insights and accelerates the identification of promising drug candidates.
The impact of AI on success rates is particularly critical. "Most programs fail in the clinic because of the early stages of the decision-making process. The focus of the next few years needs to be on increasing the success rate (the yield), rather than just efficiency. AI must help us select the right therapeutic hypotheses and the right patient populations from the start," emphasized Daphne Koller, CEO and founder of Insitro, at the Danaher Summit. This perspective highlights AI’s role in fundamentally improving the quality of early-stage decisions, which in turn leads to higher success rates in clinical development.
Defining the Modalities: A Deeper Dive
To understand the convergence, it’s essential to first delineate the characteristics, advantages, and limitations of the traditional drug modalities.
Small Molecules: These are chemically synthesized compounds, typically characterized by molecular weights below 900 Daltons. Their diminutive size is a key attribute, allowing them to readily cross cell membranes and access intracellular targets—a significant advantage for many diseases. Small molecules are generally orally bioavailable, stable at room temperature, and can be manufactured at scale with well-established regulatory and manufacturing pathways, leading to a lower cost of goods. Historically, they have been the dominant paradigm in pharmaceutical development, forming the backbone of many therapeutic arsenals.
Large Molecules (Biologics): In contrast, large molecules are derived from living organisms, encompassing a diverse array of entities such as cells, proteins, and nucleic acids. These are far more structurally complex than small molecules, typically weighing more than 1,000 Daltons. Due to their size and complexity, biologics generally cannot easily cross cell membranes and often require administration via injection or infusion. Examples include monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), messenger RNA (mRNA) therapies, CAR-T cell therapies, and engineered peptides like GLP-1 agonists. Biologics are renowned for their high specificity to their targets, which generally translates to lower off-target toxicity. However, their manufacturing and storage are more complex, often necessitating cold chain logistics, contributing to higher production costs.
The choice between these modalities is intrinsically linked to target biology. Critical considerations include the desired specificity, the characteristics of the patient population, and whether the therapeutic target is intracellular or extracellular. Modern data platforms are becoming indispensable in addressing these questions, aggregating vast amounts of published research, clinical trial data, and pipeline intelligence to inform strategic development decisions. "The choice of modality — whether I use a small molecule or any number of the large molecules — really comes down to understanding your target, understanding the biology," Matern reiterates.
Historically, small molecules faced limitations in targeting a significant portion of disease-relevant proteins, primarily those lacking well-defined binding pockets. It’s estimated that a substantial 80% of the human proteome was considered "undruggable" by traditional small molecules. This inherent limitation served as a primary catalyst for the intensive development of biologics, which possess the structural versatility to engage targets inaccessible to their smaller counterparts.
Market Dynamics and R&D Investment: A Dual Ascent
Despite earlier predictions of an impending biologic dominance, the global small molecule drug discovery market was valued at $61.9 billion in 2025 and is projected to reach $103 billion by 2031. This robust growth trajectory is being propelled by AI-accelerated hit identification, optimized lead generation, and innovative oral delivery methods. Murray Aitken from IQVIA’s 2024 data notes that while biologics indeed drive significant market value, small molecules are undergoing a "technological upgrade" through breakthroughs in induced proximity and oral delivery.
Concurrently, the global biologics market, which reached $349 billion in 2023, is forecast to surge to $1.077 trillion by 2035. This explosive growth is occurring amidst intensifying biosimilar competition, as many blockbuster biologics lose patent protection. Nevertheless, innovation pipelines remain exceptionally robust. The expansion of ADC approvals, the maturation of mRNA platform technology, the scaling of CAR-T and other cell/gene therapies, and the increasing regulatory traction of RNA-based therapies are all significant drivers of this upward trend.
The strategic approach to modality investment varies considerably across the pharmaceutical ecosystem, influenced by organizational size, existing infrastructure, and overarching strategic goals. Large pharmaceutical companies typically manage diversified portfolios that span small molecules, biologics, and nascent modalities. This allows them to absorb risk across multiple therapeutic areas and leverage extensive manufacturing infrastructure for scalability. In contrast, many biotech companies are platform-driven, built around a specific modality or proprietary technology. While this model entails higher risk concentration, it often fosters faster, more focused innovation.
"Large pharma has the privilege of running diversified portfolios across molecules, biologics — maybe they can try newer modalities so they can balance some of that risk across different therapeutic areas. Whereas smaller biotechs are often built around a specific platform… a lot of biotechs are built around, ‘we have a really clever way of doing this modality — so what can we point this modality at?’" Matern elaborates. This dynamic interdependence fuels a vibrant deal-making environment, where large pharmaceutical players often acquire or license innovative biotech platforms to gain access to novel modalities without the extensive upfront investment of building from scratch.
Small Molecule R&D: A Renaissance Underway
For many years, a prevailing narrative suggested that biologics would progressively supplant small molecules as the dominant drug modality. However, this narrative is now being actively challenged and reshaped by a confluence of AI-driven discovery, novel chemical approaches, and significant delivery innovations that are opening up previously inaccessible target classes for small molecules.
Small molecules retain several intrinsic advantages that ensure their enduring relevance: oral bioavailability, manufacturing scalability, inherent stability, intracellular access, and generally lower cost of goods. "Small molecules will remain at the foundation because they’re scalable, they’re orally delivered, they’re stable," Matern predicts. Consequently, small molecules are likely to remain the default modality for a wide array of indications, particularly in chronic conditions like metabolic and infectious diseases, where long-term, convenient administration is paramount.
One of the most transformative developments in small molecule R&D is the emergence of Targeted Protein Degradation (TPD). Unlike traditional small molecules that primarily inhibit a protein’s function, degraders such as proteolysis-targeting chimeras (PROTACs) and molecular glues operate by hijacking the cell’s own ubiquitin-proteasome system—its natural protein disposal machinery—to selectively eliminate the target protein. This revolutionary approach dramatically expands the druggable target space. Proteins that previously lacked conventional binding pockets, or were deemed too large or flexible for traditional inhibitors, now become accessible.
"Targeted protein degradation allows us to reach broader patient populations compared to injectable biologics. We are developing oral drugs with biologics-like activity, reaching critical signaling nodes that have been historically ‘undruggable’ with traditional inhibitors," stated Nello Mainolfi, CEO of Kymera Therapeutics, highlighting the potential for oral delivery of complex biologics-like activity.
Another groundbreaking frontier is RNA-targeting small molecules. Historically, RNA was considered an "undruggable" target for small molecules due to its complex and dynamic structure. However, recent advances in structural biology, high-throughput screening, and AI are overturning this long-held belief. These novel molecules are designed to bind and modulate RNA directly rather than proteins. This opens up the potential to address targets upstream of protein expression, including transcription factors and splice sites, which are often inaccessible to both traditional small molecules and most biologics. A strong commercial validation of this approach came last year when Merck Group forged a $2 billion strategic partnership with Skyhawk Therapeutics specifically to discover novel RNA-targeting small molecules for neurological disorders.
Perhaps one of the most commercially significant trends in small molecule R&D is the relentless push to achieve oral availability for complex molecules, including peptides and other structures that historically mandated injection. The GLP-1 receptor agonist story serves as the highest-profile example of this innovation. Semaglutide, initially developed as an injectable peptide, is now available in an oral formulation, with next-generation oral small molecule GLP-1 agonists actively in development.
"If you can make complex biological drugs orally available, you expand access, you make them stable, you can deliver them to remote corners of the world without worrying about a cold chain," Matern observes. Oral peptide technologies hold the promise of unlocking a new generation of drugs that combine the exquisite targeting precision of biologics with the unparalleled convenience and scalability inherent to small molecules.
Large Molecule R&D: Expanding the Therapeutic Frontier
Biologics are in the midst of a full-scale, unprecedented expansion. The biologic pipeline is more extensive, more diverse, and more technically ambitious than at any previous point in the industry’s history. What began with the pioneering development of monoclonal antibodies in the 1980s has blossomed into an entire ecosystem of sophisticated modalities, each offering distinct mechanisms of action, engaging different target classes, and catering to specific patient populations.
Biologics, particularly monoclonal antibodies, can be engineered to bind to a single target with extraordinary precision, thereby minimizing undesirable off-target effects. Proteins, receptors, and ligands located on the cell surface or circulating in the bloodstream are highly accessible to these large molecules. Many biologics offer long-lasting therapeutic effects, with some requiring only monthly or even less frequent dosing, significantly enhancing patient adherence and quality of life. From blocking specific receptors to delivering cytotoxic payloads or even editing genes, biologics offer a versatile range of mechanisms that are often unavailable to small molecules.
Monoclonal Antibodies (mAbs) remain the bedrock of the biologic pipeline. Modern mAbs are increasingly engineered for improved half-life, reduced immunogenicity, and enhanced bispecific targeting capabilities. Bispecific antibodies, for instance, are designed to simultaneously engage two distinct targets, enabling novel mechanisms such as redirecting T cells to specifically kill tumor cells. Another critical large molecule class is Antibody-Drug Conjugates (ADCs), which ingeniously combine the targeting precision of an antibody with the potent cytotoxic efficacy of a small molecule payload, delivering chemotherapy directly to cancer cells while sparing healthy tissue.
mRNA therapies have emerged as a revolutionary platform, particularly since the COVID-19 pandemic. Their rapid diversification now extends beyond infectious disease vaccines to encompass oncology vaccines, treatments for rare diseases, and other therapeutic areas. Also within the RNA space, siRNA (small interfering RNA) and antisense oligonucleotides (ASOs) represent RNA interference approaches that effectively silence disease-causing genes at the mRNA level. These modalities have gained significant regulatory approvals in rare diseases and cardiovascular indications, showcasing their potential to address genetic disorders.
CAR-T cell therapies represent a pinnacle of personalized medicine, utilizing a patient’s own T cells, which are genetically engineered to recognize and destroy cancer cells. These therapies have been transformative in the treatment of hematologic malignancies, with intensive research underway to extend their efficacy to solid tumors. Furthermore, CRISPR and other gene editing technologies are advancing rapidly, with the first approved CRISPR therapy reaching patients in 2023, marking a historic milestone in the ability to directly modify the human genome to correct disease-causing mutations.
Oncology remains the single largest driver of R&D investment in biologics, and it is the therapeutic area where the most ambitious and cutting-edge large molecule science is being deployed. ADCs, in particular, have experienced a wave of regulatory approvals and robust late-stage pipeline activity, with over 100 ADCs currently in clinical development globally. Immuno-oncology, encompassing checkpoint inhibitors, CAR-T therapies, and bispecific antibodies, continues its expansion, progressively moving from highly successful applications in hematologic cancers into the more challenging landscape of solid tumors.
The GLP-1 Story: A Case Study in Biologic Validation and Lifecycle Innovation
The phenomenon surrounding GLP-1 receptor agonists provides a compelling illustration of the immense commercial and scientific power of large molecule R&D, and simultaneously, how it can catalyze innovation in small molecules. Drugs like semaglutide and tirzepatide have rapidly ascended to become among the best-selling pharmaceuticals in history, validating the efficacy and potential of peptide engineering on a scale previously unseen in the industry.
Crucially, the GLP-1 story also serves as a prime example of lifecycle innovation—how initial biologic validation can powerfully drive subsequent small molecule development. "GLP-1 is really showing how that balance is evolving. They are a peptide-based modality — technically in the large molecule category — but the commercial success is now driving innovation across small molecules: oral delivery and combination therapy," Matern explains. "I think we’ll see that pattern repeat. Historically, many therapies start as injectables because it’s technically simpler to deliver a complicated molecule that way. But once you get the validation of the biology and the commercial demand becomes clear, there’s a really strong investment incentive to invest in more convenient formats."
The journey of GLP-1 agonists from injectable peptides to orally available small molecule formulations is poised to become a template for future modality evolution across numerous therapeutic areas, underscoring the dynamic interplay and synergistic potential between small and large molecules.
Strategic Implications for a Convergent Future
The convergence of small and large molecules presents distinct strategic imperatives for various stakeholders across the pharmaceutical ecosystem:
-
For Large Pharma: The mandate is clear: strategic portfolio diversification across all modalities, substantial investment in robust data infrastructure to leverage AI, and proactive strategic acquisition or licensing of innovative platform biotechs before their valuations fully reflect clinical validation. This ensures access to cutting-edge technologies and broadens therapeutic reach.
-
For Biotechs: Maintaining a strong platform focus remains a key strength. However, the most fundable and partnerable propositions will be those that combine a truly novel modality with a well-validated target and a clear, pragmatic path to oral or other highly convenient delivery methods. This addresses a critical market need for patient-friendly formulations.
-
For Investors: Prudent investment strategies should prioritize companies that are at the forefront of delivery technology innovation. Attention should be paid to organizations that are effectively solving the "last-mile problem" of safely and conveniently delivering complex molecules to their intended targets within the body. Data platform companies enabling this convergence are also key.
-
For Researchers and R&D Teams: The data foundation is rapidly becoming the new laboratory bench. Investing in comprehensive Electronic Laboratory Notebooks (ELNs), developing robust ontologies, and implementing structured data capture from the very first day of a project is no longer optional. This commitment to FAIR (Findable, Accessible, Interoperable, Reusable) data principles is essential for fueling AI-powered drug discovery and maximizing research efficiency.
Conclusion: Beyond Competition, Towards Collaboration
The evolving relationship between small and large molecules is fundamentally not a competition for dominance. Instead, it represents a dynamic and expanding spectrum of therapeutic possibilities, where the "gray area" between these modalities is growing exponentially.
"I don’t see small and large molecules competing for dominance. I think there’s going to be a continued balance… small molecules will remain at the foundation because they’re scalable, they’re orally delivered, they’re stable. And biologics will probably be where we continue to expand, where things like precision and durability matter," Matern concludes. This perspective emphasizes a synergistic future where each modality plays to its strengths, often in concert with others.
The profound shift from a laborious, often serendipitous process of trial and error to a data-driven, predictive model of R&D is arguably the most consequential change in drug discovery in a generation. Organizations are increasingly making significant investments in data quality, robust governance frameworks, and seamless data integration to fully harness the power of AI in drug discovery.
Ultimately, scientific insight alone, however brilliant, is insufficient. The enduring challenge of drug discovery remains getting the right drug to the right target in the right patient. Breakthroughs in lipid nanoparticles for mRNA delivery, advanced oral peptide technologies, sophisticated ADC linker chemistry, and next-generation formulation science represent the vanguard of innovation that will drive the next wave of therapeutic success.
The expansion of the pharmacological toolkit, encompassing an increasingly diverse array of modalities and delivery systems, is unequivocally good news for patients, for scientific advancement, and for the pharmaceutical industry as a whole. More tools translate directly into the ability to address more targets, treat a wider spectrum of diseases, and ultimately reach more patients with effective therapies. In this integrated future, competition is not between modalities themselves, but rather between organizations that wholeheartedly embrace this newfound complexity and those that fail to adapt.
Leave a Reply